20 articles
A Phase 1/2 NCI trial tested PANVAC vaccinia and fowlpox vaccines plus immune booster sargramostim in advanced colorectal, breast, and ovarian cancers.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
New viral therapy ASP9801 targets solid tumors directly, potentially offering hope for patients with advanced metastatic cancer.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
First study tests whether supervised exercise training is safe and beneficial for bladder cancer patients during treatment.
A completed Phase 2 trial explores whether low-dose continuous chemotherapy can boost immunotherapy efficacy in advanced lung cancer.
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
Autologous NK cell therapy combined with immunotherapy tested in 27 patients with treatment-resistant cancers.
Stanford researchers used smartwatches and blood tests to monitor dangerous side effects during cutting-edge CAR-T cancer treatment.
Phase 3 trial compared therapeutic vaccine OSE2101 to chemotherapy in 219 lung cancer patients after immunotherapy failure.
French researchers test intraperitoneal nivolumab after surgery and heated chemotherapy for advanced ovarian cancer patients.
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
HIIT training studied in 52 men with prostate cancer on active surveillance to evaluate exercise benefits during watchful waiting.
A completed pilot trial tested physical therapy and progressive muscle relaxation to preserve function and mood in older adults with advanced lung cancer.
A Phase 1/2 trial tests a custom cancer vaccine paired with checkpoint inhibitors in patients with advanced solid tumors.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
A phase I trial tests SD-101, nivolumab, and radiation together against metastatic pancreatic cancer that has stopped responding to chemo.
A Phase 2 trial examines whether adding the anti-angiogenic drug bevacizumab to standard chemo improves outcomes in pediatric sarcoma.
Phase II trial tested nivolumab with or without ipilimumab in 164 patients with metastatic sarcoma that couldn't be surgically removed.
